Dr. James L. Januzzi JR., MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- New York Medical College (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 317
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: New York Medical College
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
MA license 150914 -
Internal Medicine Physician
MA license 150914
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- North Shore Medical Center - Salem, MA
- Wentworth-Douglass Hospital Dover, NH
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 317
- Services billed
- 827
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 273 | 235 |
| Established patient office or other outpatient visit, 30-39 minutes | 217 | 198 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 129 | 50 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 92 | 49 |
| Established patient office or other outpatient visit, 40-54 minutes | 89 | 77 |
| Hospital discharge day management, more than 30 minutes | 50 | 50 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 48 | 48 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Boston, MA | 387 |
| Metoprolol Succinate Other prescribers in Boston, MA | 306 |
| Eliquis (apixaban) Other prescribers in Boston, MA | 183 |
| Jardiance (empagliflozin) Other prescribers in Boston, MA | 159 |
| Spironolactone Other prescribers in Boston, MA | 144 |
| Amlodipine Besylate Other prescribers in Boston, MA | 141 |
| Ezetimibe Other prescribers in Boston, MA | 121 |
| Rosuvastatin Calcium Other prescribers in Boston, MA | 120 |
| Entresto (sacubitril/valsartan) Other prescribers in Boston, MA | 117 |
| Lisinopril Other prescribers in Boston, MA | 108 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 50 payments worth $130,722 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $49,600 |
|---|---|
| Roche Diagnostics International LTD | $11,256 |
| Abbott Laboratories | $10,809 |
| Boehringer Ingelheim International GmbH | $9,293 |
| Siemens Medical Solutions USA, Inc. | $5,750 |
| Alnylam Pharmaceuticals Inc. | $5,472 |
| Beckman Coulter, Inc. | $5,400 |
| Amgen Inc. | $4,601 |
| Consulting Fee | $113,822 |
|---|---|
| Speaking at a medical education program | $8,250 |
| Compensation for services other than consulting (speaking, faculty) | $5,750 |
| Honoraria | $2,500 |
| Food and Beverage | $401 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. May 15, 2025 | Consulting Fee | $18,750 |
| Alexion Pharmaceuticals, Inc. Mar 15, 2025 | Consulting Fee | $15,250 |
| Alexion Pharmaceuticals, Inc. Apr 15, 2025 | Consulting Fee | $9,000 |
| Abbott Laboratories Apr 1, 2025 | Speaking at a medical education program ALINITY · Core Diagnostics | $6,000 |
| Siemens Medical Solutions USA, Inc. Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,750 |
| Roche Diagnostics International LTD Feb 3, 2025 | Consulting Fee | $5,670 |
| Alnylam Pharmaceuticals Inc. Jul 24, 2025 | Consulting Fee | $5,250 |
| Amgen Inc. Feb 4, 2025 | Consulting Fee | $4,524 |
| Roche Diagnostics International LTD Dec 1, 2025 | Consulting Fee | $4,326 |
| Eli Lilly and Company May 7, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $4,000 |
All 45 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Siemens Medical Solutions USA, Inc. Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,750 |
| Roche Diagnostics International LTD Dec 1, 2025 | Consulting Fee | $4,326 |
| Boehringer Ingelheim International GmbH Oct 15, 2025 | Consulting Fee | $1,770 |
| Beckman Coulter, Inc. Oct 7, 2025 | Consulting Fee Access BNP · Devices | $1,800 |
| Abbott Laboratories Sep 22, 2025 | Speaking at a medical education program ALINITY · Core Diagnostics | $2,250 |
| Pfizer Inc. Sep 8, 2025 | Consulting Fee | $1,200 |
| Perspectum Diagnostics LTD Jul 31, 2025 | Consulting Fee | $3,200 |
| Perspectum Diagnostics LTD Jul 31, 2025 | Consulting Fee | $800 |
| E.r. Squibb & Sons, L.l.c. Jul 28, 2025 | Consulting Fee | $350 |
| Alnylam Pharmaceuticals Inc. Jul 24, 2025 | Consulting Fee | $5,250 |
| Pfizer Inc. Jun 30, 2025 | Consulting Fee | $600 |
| Boehringer Ingelheim International GmbH Jun 26, 2025 | Consulting Fee | $1,770 |
| Polymedco, LLC Jun 17, 2025 | Honoraria | $2,500 |
| Abbott Laboratories Jun 11, 2025 | Consulting Fee TENDYNE · Structural Heart | $325 |
| E.r. Squibb & Sons, L.l.c. Jun 3, 2025 | Consulting Fee | $2,100 |
| E.r. Squibb & Sons, L.l.c. Jun 3, 2025 | Consulting Fee | $900 |
| Pfizer Inc. May 27, 2025 | Consulting Fee | $600 |
| Alexion Pharmaceuticals, Inc. May 15, 2025 | Consulting Fee | $18,750 |
| Pfizer Inc. May 12, 2025 | Consulting Fee | $600 |
| Eli Lilly and Company May 7, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $4,000 |
| Abbott Laboratories Apr 30, 2025 | Consulting Fee TENDYNE · Structural Heart | $325 |
| F. Hoffmann-la Roche AG Apr 28, 2025 | Consulting Fee | $3,220 |
| Boehringer Ingelheim International GmbH Apr 23, 2025 | Consulting Fee | $3,540 |
| Alexion Pharmaceuticals, Inc. Apr 15, 2025 | Consulting Fee | $9,000 |
| Beckman Coulter, Inc. Apr 8, 2025 | Consulting Fee Access BNP · Devices | $3,600 |
| Abbott Laboratories Apr 2, 2025 | Consulting Fee TENDYNE · Structural Heart | $325 |
| Abbott Laboratories Apr 1, 2025 | Speaking at a medical education program ALINITY · Core Diagnostics | $6,000 |
| Abbott Laboratories Mar 31, 2025 | Consulting Fee TENDYNE · Structural Heart | $609 |
| Abbott Laboratories Mar 26, 2025 | Consulting Fee TENDYNE · Structural Heart | $325 |
| Alexion Pharmaceuticals, Inc. Mar 15, 2025 | Consulting Fee | $15,250 |
| Roche Diagnostics International LTD Mar 12, 2025 | Consulting Fee | $1,260 |
| AbbVie Inc. Feb 18, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $600 |
| Alexion Pharmaceuticals, Inc. Feb 15, 2025 | Consulting Fee | $2,500 |
| Alexion Pharmaceuticals, Inc. Feb 15, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $600 |
| Abbott Laboratories Feb 12, 2025 | Consulting Fee TENDYNE · Structural Heart | $650 |
| E.r. Squibb & Sons, L.l.c. Feb 7, 2025 | Consulting Fee | $700 |
| Amgen Inc. Feb 4, 2025 | Consulting Fee | $4,524 |
| Roche Diagnostics Corporation Feb 4, 2025 | Consulting Fee None | $900 |
| Roche Diagnostics International LTD Feb 3, 2025 | Consulting Fee | $5,670 |
| Boehringer Ingelheim International GmbH Jan 31, 2025 | Consulting Fee | $2,213 |
| Alexion Pharmaceuticals, Inc. Jan 15, 2025 | Consulting Fee | $2,000 |
| Alexion Pharmaceuticals, Inc. Jan 15, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $1,500 |
| AstraZeneca UK Limited Jan 13, 2025 | Consulting Fee | $650 |
| Radiometer America, Inc Jan 8, 2025 | Consulting Fee | $3,720 |
| Roche Diagnostics Corporation Jan 8, 2025 | Consulting Fee None | $1,800 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $266,922 in research payments for these studies, mostly to the institutions running them.
- Optimizing Guideline Directed Medical Therapy for Heart Failure in Cardiology Practice the Trial for Evaluating Accelerated Guideline Directed Medical Therapy for Heart Failure at Massachusetts General Hospital (TEAM-…
AstraZeneca Pharmaceuticals LP - EXPAND II
Medtronic, Inc. - Study name not reported
E.r. Squibb & Sons, L.l.c. - ALLEVIATE-HF
Medtronic, Inc. - A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
AstraZeneca UK Limited - Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics (USA) Inc. · Recruiting · NCT05064709 - FIRE-HFpEF
Medtronic, Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.